Serum-free suspension system for lentiviral production
A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.
1. A lentiviral vector production system comprising:
a) suspension 293 cells;
b) a lentiviral culture supplement to control cell growth in cell culture medium, wherein the lentiviral culture supplement comprises amino acids and sugar sources and has an osmolality of about 1000 mOsm/kg to about 1500 mOsm/kg, and wherein the lentiviral culture supplement is for use at from about 1% to about 10%, volume/volume, of cell culture medium,
c) a lipid aggregate transfection reagent comprising a cationic lipid and at least one helper and/or neutral lipid, and
d) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine,
wherein the lentiviral vector production system is serum-free and designed for production of lentivirus in the 293 cells.
2. The lentiviral production system of claim 1 , wherein the cationic lipid comprises dihydroxyl-dimyristylspermine tetrahydrochloride (DHDMS).
3. The lentiviral production system of claim 1 , wherein the at least one helper and/or neutral lipid comprises dioleoylphosphatidylethanolamine (DOPE).
4. The lentiviral production system of claim 1 , wherein the at least one helper and/or neutral lipid comprises DOPE and cholesterol.
5. The lentiviral vector production system of claim 1 , wherein the suspension 293 cells have been adapted for growth under high density conditions.
6. The lentiviral vector production system of claim 1 , wherein the suspension 293 cells are 293F cells, or a derivative thereof.
7. The lentiviral vector production system of claim 6 , wherein the 293F cells, or the cells derived therefrom, are capable of growing at a density of from about 1×10 6 to about 20×10 6 with less than 20% cell death after 5 days.
8. The lentiviral vector production system of claim 1 , wherein the lentiviral culture supplement further comprises:
dipeptides, sugar alcohol, and/or carbon sources.
9. The lentiviral vector production system claim 1 , wherein the lentiviral culture supplement comprises glucose.
10. The lentiviral vector production system of claim 1 , wherein the lentiviral culture supplement further comprises
minerals and/or trace metals, and/or
vitamins and/or vitamin precursors.
11. The lentiviral vector production system of claim 1 , wherein the lentiviral culture supplement is for use at about 1%, 3.5%, 5%, or 10%, volume/volume.
12. The lentiviral vector production system of claim 9 , wherein the osmolality of said glucose in the lentiviral culture supplement is from about 500 mOsm/kg to about 700 mOsm/kg, about 550 mOsm/kg to about 650 mOsm/kg, or about 575 mOsm/kg to about 625 mOsm/kg.
13. The lentiviral vector production system of claim 9 , wherein the concentration of said glucose in the lentiviral culture supplement is from about 85 mg/ml to about 115 mg/ml, about 90 mg/ml to about 110 mg/ml, or about 95 mg/ml to about 105 mg/ml.
14. The lentiviral vector production system of claim 1 , wherein the lentiviral culture supplement has an osmolality of about 1100 mOsm/kg, about 1150 mOsm/kg, about 1200 mOsm/kg, about 1250 mOsm/kg, about 1300 mOsm/kg, about 1350 mOsm/kg, about 1400 mOsm/kg, about 1450 mOsm/kg, or about 1500 mOsm/kg.
15. The lentiviral vector production system of claim 2 , wherein the DHDMS is included at from about 0.4 to 0.6 mM.
16. The lentiviral vector production system of claim 1 , wherein the lentiviral enhancer further comprises valproic acid.
17. The lentiviral vector production system of claim 1 , wherein sodium propionate and/or sodium butyrate are provided in an aqueous solution.
18. The lentiviral vector production system of claim 1 , wherein sodium propionate is included at from about 3 to 15 mM, about 3 to 5 mM, or about 5 to 8 mM.
19. The lentiviral vector production system of claim 1 , wherein sodium butyrate is included at from about 1.5 to 3 mM, from about 1.5 to 2.5 mM, or about 2.5 to 3 mM.
20. The lentiviral vector production system of claim 1 , wherein caffeine is included at from about 0.75 to 3 mM, from about 2 to 3 mM, or from about 1 to 2 mM.
21. The lentiviral vector production system of claim 16 , wherein valproic acid is included at from about 0.5 to 1 mM.
22. The lentiviral vector production system of claim 1 , wherein the lentiviral production enhancer comprises sodium propionate at from about 3 to 15 mM, sodium butyrate at from about 1.5 to 3 mM, and caffeine at from about 0.75 to 3 mM.
23. The lentiviral vector production system of claim 1 , wherein the enhancer comprises sodium propionate at from about 7.5 to 15 mM, sodium butyrate at from about 1.5 to 3 mM, and caffeine at from about 0.75 to 1.5 mM.
24. The lentiviral production system of claim 1 , wherein each of the amino acids has a concentration of about 0.1 mg/ml to about 8 mg/ml.